You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
ADMA Biologics is an end-to-end biopharmaceutical company with three FDA-licensed approved products including ASCENIV™ (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (hepatitis B immune globulin, human). ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.
Beyond the present focus on the commercial development of ASCENIV™ and expansion of our plasma collection facilities, there are a number of additional opportunities for growth, including: